Noncompetitive Antagonists of Dopamine Reuptake Inhibitors'', based on U.S. Provisional Patent Application Serial No. 60/030,248, filed October 31, 1996, to Trillium Neuroscience Inc., having a place of business in Washington, DC. The patent rights in this invention have been assigned to the United States of America.

DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 27, 1998 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Leopold J. Luberecki, Jr., J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Box 13, Rockville, MD 20852–3804; Telephone: (301) 496–7735, ext. 223; Facsimile: (301) 402–0200.

SUPPLEMENTARY INFORMATION: In an effort to develop an efficacious treatment for cocaine addiction, this invention describes sustained-release derivatives of hydroxylated analogs of substituted 1-(2-[bis(aryl)methoxy]ethyl)-piperazines and -homopiperazines. These compounds bind to the dopamine transporter but do not inhibit dopamine reuptake, thereby providing a sustained increase in the level of extracellular dopamine and providing the drug abuser with some relief from drug craving due to dopamine deficiency, yet they simultaneously inhibit cocaine from further elevating the level of extracellular dopamine and increasing the probability of additional toxic side effects. The invention provides the sustained-release derivatives, pharmaceutical compositions comprising the same, and a method of using such sustained released derivatives as a treatment for cocaine addiction.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to the use of the invention for the development of pharmaceutical compounds to treat drug addiction.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: May 18, 1998.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 98–14139 Filed 5–27–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

National Institute of Environmental Health Sciences National Toxicology Program; Request for Comments on Chemicals Nominated to the National Toxicology Program (NTP) for Toxicology Studies—Recommendations by the Interagency Committee for Chemical Evaluation and Coordination (ICCEC) for Study, No Studies, or Deferral to Obtain Additional Information

Background

As part of an effort to earlier inform the public and obtain input into the selection of chemicals for evaluation, the National Toxicology Program (NTP) routinely seeks public input on (1) chemicals nominated to the Program for toxicological studies, and (2) the testing recommendations made by the ICCEC, the Federal interagency committee that serves as the first level of review for nominations. Summaries of the ICCEC's recommendations and public comments received on the nominated chemicals are next presented to the NTP Board of Scientific Counselors (the Program's external scientific advisory committee) for their review and comment in an open, public session. The ICCEC recommendation, Board recommendations, and public comments are incorporated into the recommendations that are then submitted to the NTP Executive Committee, the Federal interagency policy oversight body. The Executive Committee reviews and approves action to move forward to test, defer, or delete on each of the nominated chemicals for the various types of study, and recommends priorities.

Request for Comment

Interested parties are encouraged to comment on the recommendations and provide information on the chemicals listed below. The Program would welcome receiving toxicology and carcinogenesis information from completed or ongoing studies, and information on planned studies, as well as current production data, human exposure information, use patterns, and environmental occurrence for any of the chemicals listed in this announcement. To provide comments or information, please contact Dr. William Eastin at the address given below within 60 days of the appearance of this announcement.

At their meeting on April 23, 1998, the ICCEC reviewed 18 agents nominated to the NTP for consideration to study and recommended 11 chemicals for absorption, toxicity, or carcinogenicity studies, recommended that no studies be performed on 4 chemicals, and deferred 3 substances pending receipt of test data from other organizations or from related studies in progress by the NTP, and information on production, exposure, and use patterns. Chemicals with CAS numbers, nomination source types of studies under consideration, and other information are given in the following tables.

Contact may be made by mail to: Dr. William Eastin, NIEHS/NTP, P.O. Box 12233, Research Triangle Park, North Carolina 27709; by telephone at (919) 541–7941; by FAX at (919) 541–3687; or by email at Eastin@NIEHS.GOV.

Dated: May 18, 1998.

Samuel H. Wilson,

Deputy Director, National Toxicology Program.

Attachment

CHEMICALS NOMINATED TO THE NTP FOR STUDY, AND TESTING RECOMMENDATIONS MADE BY THE ICCEC ON APRIL 23, 1998

Chemical [CAS No.]	Nominated by	Recommended for	Study rationale; other information
Chemicals Recommended for Testing			
Bixin (Annatto) [6973–79–5 (1393–63–1)].	NCI	—Genetic toxicity —Subchronic toxicity	—Widespread human exposure. —Natural product.
Diethyl amine [109–89–7]	NIEHS	—Subchronic toxicity —Ocular toxicity —Carcinogenicity	—High production. —Also present in foods. —Widespread human exposure.
Dihydroxyacetone [96–26–4].	NCI	—Skin absorption	—Widely used as component of tanning compounds. —Natural product of metabolism.
Fenchone, α-, l-, d-, [1195–79–5 (α-); 7787–20–4 (l-); 4695–62–9 (d-)].	NCI	—Genetic toxicity —Defer prechronic studies pending completion and evaluation of NTP camphor study	—Natural product. —Used as flavoring. —Widespread human exposure. —Production, usage, and exposure data requested.
Isopropylamine [75–31–0]	NIEHS	—Subchronic toxicity —Ocular toxicity —Carcinogenicity (through TSCA–ITC)	—High production. —Also present in foods. —Widespread human exposure.
Pulegone [89–82–7] Menthofuran (494–90–6].	NIEHS	—Toxicologic characterization —Carcinogenicity study with pulegone	—Natural product. —Used as flavoring. —Widespread human exposure. —Menthofuran is a metabolite of pulegone.
α-Solanine [20562–02–1	(1)	—Carcinogenicity	—Natural product. —Widespread human exposure. —Known human toxicant.
α-Thujone (546–80–5]	NCI	—Genetic toxicity —Neurotoxicity —Subchronic toxicity —Multigeneration reproductive toxicity	—Natural product. —Component of food flavoring additives. —Banned as direct food additive by FDA.
Triethylamine [121–44–8]	UAW	—Subchronic toxicity —Ocular toxicity —Carcinogenicity (through TSCA–ITC)	—High production. —Known worker exposure.
Trigonelline [535–83–1] ...	(1)	—Toxicologic characterization —Metabolic differences between humans and rodents	—Plant hormone. —Widespread human exposure through diet.

[1] Private Individual.

Chemical [CAS No.]	Nominated by	Recommended for	Rationale; other information
Chemicals For Which No Testing Is Recommended			
β-Caryophyllene [87–44–5].	NCI	—Subchronic toxicity; metabolism; cell transformation; consider for carcinogenicity.	—Insufficient use to warrant testing.
α-Cubebene [17699–14–8].	NCI	—metabolism	—Insufficient use to warrant testing.
Orthanilic acid [88–21–1].	NIEHS	—Carcinogenicity	—Low production; little, if any, exposure to the population.
2-Phenethyl alcohol (60–12–8].	(1)	—Carcinogenicity	—No suspicion for carcinogenicity based on structure and genetic toxicity tests.
Chemicals Deferred for Additional Information			
α-Chaconine [20562–03–2].	(1)	—Carcinogenicity	—Defer testing pending results of α-solanine studies.
St John's Wort Hypericin [548–04–9].	NCI	—Carnogenicity (St. John's Wort); genetic toxicity and carcinogenicity (hypericin). —Defer pending NTP evaluation of carcinogenicity testing being performed by industry.	—Herbal remedy in widespread use. —NCI clinical trial in progress. —Industry has completed subchronic toxicity studies and is completing a rodent carcinogenicity study using St. John's Wort.

[1] Private Individual.

[FR Doc. 98–14138 Filed 5–27–98; 8:45 am]
BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Fiscal Year (FY) 1998 Funding Opportunities

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice of funding availability.

SUMMARY: The Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Substance Abuse Prevention (CSAP) announces the availability of FY 1998 funds for grants for the following activity. This activity is discussed in more detail under Section 4 of this notice. This notice is not a complete description of the activity; potential applicants must obtain a copy of the Guidance for Applicants (GFA) before preparing an application.

Activity	Application deadline	Estimated funds available	Estimated No. of awards	Project period
Faculty Development Program	7/28/98	$1.0M	10	3 yrs.

Note: SAMHSA also published notices of available funding opportunities for FY 1998 in the **Federal Register** on January 6, 1998, January 20, 1998, February 26, 1998, March 20, 1998, April 8, 1998, April 16, 1998, April 20, 1998, and on April 22, 1998.

The actual amount available for awards and their allocation may vary, depending on unanticipated program requirements and the volume and quality of applications. Awards are usually made for grant periods from one to three years in duration. FY 1998 funds for activities discussed in this announcement were appropriated by the Congress under Public Law No. 105–78. SAMHSA's policies and procedures for peer review and Advisory Council review of grant and cooperative agreement applications were published in the **Federal Register** (Vol. 58, No. 126) on July 2, 1993.

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of Healthy People 2000, a PHS-led national activity for setting priority areas. The SAMHSA Centers' substance abuse and mental health services activities address issues related to Healthy People 2000 objectives of Mental Health and Mental Disorders; Alcohol and Other Drugs; Clinical Preventive Services; HIV Infection; and Surveillance and Data Systems. Potential applicants may obtain a copy of Healthy People 2000 (Full Report: Stock No. 017–001–00474–0) or Summary Report: Stock No. 017–001–00473–1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402–9325 (Telephone: 202–512–1800).

General Instructions: Applicants must use application form PHS 5161–1 (Rev. 5/96; OMB No. 0937–0189). The application kit contains the GFA (complete programmatic guidance and instructions for preparing and submitting applications), the PHS 5161–1 which includes Standard Form 424 (Face Page), and other documentation and forms. Application kits may be obtained from the organization specified for each activity covered by this notice (see Section 4).

When requesting an application kit, the applicant must specify the particular activity for which detailed information is desired. This is to ensure receipt of all necessary forms and information, including any specific program review and award criteria.

The PHS 5161–1 application form and the full text of each of the activities (i.e., the GFA) described in Section 4 are available electronically via SAMHSA's World Wide Web Home Page (address: http://www.samhsa.gov).

Application Submission: Unless otherwise stated in the GFA, applications must be submitted to: SAMHSA Programs, Center for Scientific Review, National Institutes of Health, Suite 1040, 6701 Rockledge Drive MSC–7710, Bethesda, Maryland 20892–7710*

(*Applicants who wish to use express mail or courier service should change the zip code to 20817.)

Application Deadlines: The deadlines for receipt of applications are listed in the table above. Please note that the deadlines may differ for the individual activities.

Competing applications must be received by the indicated receipt date(s) to be accepted for review. An application received after the deadline may be acceptable if it carries a legible proof-of-mailing date assigned by the carrier and that date is not later than one week prior to the deadline date. Private metered postmarks are not acceptable as proof of timely mailing.

Applications received after the deadline date and those sent to an address other than the address specified in the GFA will be returned to the applicant without review.

FOR FURTHER INFORMATION CONTACT: Requests for activity-specific technical information should be directed to the program contact person identified for each activity covered by this notice (see Section 4).

Requests for information concerning business management issues should be directed to the grants management contact person identified for each activity covered by this notice (see Section 4).

SUPPLEMENTARY INFORMATION: To facilitate the use of this Notice of Funding Availability, information has been organized as outlined in the Table of Contents below. For each activity, the following information is provided:

- Application Deadline
- Purpose.
- Priorities.
- Eligible Applicants.
- Grants/Cooperative Agreements/Amounts.
- Catalog of Federal Domestic Assistance Number.
- Contacts.
- Application Kits.

Table of Contents

1. Program Background and Objectives
2. Special Concerns
3. Criteria for Review and Funding
   3.1 General Review Criteria
   3.2 Funding Criteria for Scored Applications
4. Special FY 1998 Substance Abuse and Mental Health Services Activities
   4.1 Grants
   4.1.1 Faculty Development Program—Faculty Developing People, Programs, Products and Policies for Integrated Service Delivery
5. Public Health System Reporting Requirements